Latest market price
25.87
-1.36-4.99%
OverviewShort InterestFilings
BEAMQT40Beam Therapeutics Inc.·NASDAQ
25.87-4.99%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
VRDN+2.55%$25.30NRIX-4.10%$25.70MBX-2.63%$54.40TLX-0.55%$9.05DNLI-0.42%$18.86IDYA-1.00%$31.64ADMA-3.07%$11.06IRON-2.75%$78.62
Snapshot
Index—P/E—EPS (ttm)-0.86Insider Own14.16%Shs Outstand103.29MPerf Week13.22%
Market Cap2.81BForward P/E—EPS next Y-4.82Insider Trans-2.75%Shs Float88.33MPerf Month11.64%
Enterprise Value1.89BPEG—EPS next Q-1.15Short Float29.71%Perf Quarter5.09%
Income-86.00MP/S18.03EPS this Y—Short Ratio14.29Perf Half Y-11.30%
Sales156.00MP/B2.64EPS next Y—ROA-6.16%Short Interest26.24MPerf YTD-1.77%
Book/sh10.33P/C2.44EPS next 5Y—ROE-7.70%52W High38.26 -32.38%Perf Year9.93%
Cash/sh11.16P/FCF—EPS past 3/5Y—ROIC-28.62%52W Low20.23 27.88%Perf 3Y40.80%
Dividend Est.—EV/EBITDA—Sales past 3/5Y31.91% —Gross Margin—Volatility7.94% 5.81%Perf 5Y-70.95%
Dividend TTM—EV/Sales12.13EPS Y/Y TTM—Oper. Margin-242.27%ATR (14)1.57Perf 10Y—
Dividend Ex-DateNov 04, 2013Quick Ratio14.57Sales Y/Y TTM164.41%Profit Margin-54.75%RSI (14)57.69Recom2.37
Dividend Gr. 3/5Y—Current Ratio14.57EPS Q/Q-18.00%SMA208.17%Beta2.21Target Price66.00
Payout0.00%Debt/Eq0.22Sales Q/Q-100.00%SMA505.02%Rel Volume0.81Prev Close27.23
Employees540LT Debt/Eq0.22EarningsNov 03SMA200-3.23%Avg Volume1.85MPrice25.87
IPO DateFeb 06, 2020Option/ShortYes / YesEPS/Sales Surpr.-6.66% -97.01%Net Debt/EBITDA—Volume1,497,885Change-4.99%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-29-26ReiteratedCanaccord Genuity$78 → $79
May-21-26ReiteratedH.C. WainwrightBuy$80
May-13-26ReiteratedTudor Pickering$40 → $39
Feb-25-26ReiteratedRBC CapitalSector Perform$26
Feb-20-26InitiatedCanaccordBuy$74
Jan-21-26ReiteratedTudor Pickering$37 → $41
Jan-07-26ReiteratedUBS$28
Nov-24-25InitiatedEvercore ISIOutperform$35
Oct-09-25InitiatedJefferiesBuy$41
May-07-25ReiteratedGuggenheimBuy$55
Latest News· Times ET
Oct-30-26
Oct-30-2611:11AM
3 Promising Genomics Stocks to Add to Your Portfolio Nowzacks.com
Oct-29-26
Oct-29-2605:51AM
Beam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last?zacks.com
Oct-27-26
Oct-27-2601:10PM
Beam Therapeutics Inc. (BEAM) Reviews Initial Phase I II BEAM-301 Data in Glycogen Storage Disease Type 1a Transcriptseekingalpha.com
11:07AM
Beam Therapeutics Reports Early BEAM-301 Gains in GSD1a Fasting Tolerancemarketbeat.com
07:00AM
Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congressglobenewswire.com
03:11AM
Beam Therapeutics Announces Initial Data From Its Ongoing Phase 1/2 Clinical Trial Evaluating BEAM-301 For Treatment Of Glycogen Storage Disease Type Ia; In The 40 Mg Cohort, Two Patients Achieved 15 Hours Of Controlled Fasting; Safety Profile Of BEAM-301 Consistent With LNP-Based TherapiesBenzinga
Oct-19-26
Oct-19-2604:22AM
Insider Selling: Beam Therapeutics (NASDAQ:BEAM) CEO Sells $589,250.00 in Stockdefenseworld.net
Oct-17-26
Oct-17-2609:00PM
Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?fool.com
Oct-15-26
Oct-15-2610:00AM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAMprnewswire.com
Oct-13-26
Oct-13-2606:03PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAMglobenewswire.com
07:00AM
Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congressglobenewswire.com
04:45AM
Top 10 Powder Keg Stocks Where Short Sellers Are Sitting on a FuseBenzinga
Oct-06-26
Oct-06-2604:48PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAMglobenewswire.com
Sep-30-26
Sep-30-2609:23PM
Will IP Theft Allegations Against YolTech and Serapha Bio Change Beam Therapeutics' (BEAM) NarrativeYahoo
Sep-29-26
Sep-29-2605:39PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAMglobenewswire.com
Company

Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue15614064378—————
Cost of Goods Sold Incl. D&A0223680—————
Gross Profit156117-304378—————
Selling, General and Administrative Excl. Other125114112117—————
Research and Development409410368437—————
Other Operating Expense1-23-3680—————
Operating Income-378-384-416-176—————
Interest Expense04400—————
Unusual Expense
—————————
Non-Operating Income (Expense)2933473945—————
Net Income Before Taxes-86-80-377-131—————
Income Taxes0001—————
Consolidated Net Income-86-80-377-133—————
Net Income From Continuing Operations-86-80-377-133—————
Net Income-86-80-377-133—————
EPS (Recurring)-0.82-0.81-4.58-1.72—————
EPS (Basic, Before Extraordinaries)-0.82-0.81-4.58-1.72—————
EPS (Diluted)-0.86-0.81-4.58-1.72—————
EBITDA-63-14-355-111—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio17.2519.6031.785.54—————
Gross Margin100.0083.57-475.00100.00—————
Operating Margin-242.31-274.29-650.00-46.56—————
Net Margin-55.13-57.14-589.06-35.19—————
Shares Outstanding104998277—————
Market Capitalization2,6902,7442,0342,096—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$41.16$34.14$27.12$20.09$13.07● Close Price0.00M2.95M5.90M8.85M11.80MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Evans John M.CEOOct 16 '26Sale23.9825,000599,5951,047,205Oct 16
Evans John M.CEOOct 16 '26Option Exercise1.0325,00025,7501,072,205Oct 16
Evans John M.CEOOct 15 '26Option Exercise1.0325,00025,750180,804Oct 16
Evans John M.CEOOct 15 '26Sale23.5725,000589,1501,047,205Oct 16
Cavanagh Bethany JSVP, Finance and TreasurerOct 01 '26Sale24.411874,56550,984Oct 02
Simon AmyChief Medical OfficerJul 27 '26Sale25.7416,667429,03785,696Jul 29
Simon AmyChief Medical OfficerJun 30 '26Sale34.7337312,954102,363Jul 02
Evans John M.CEOJun 30 '26Option Exercise1.0325,00025,7501,072,205Jul 01
Evans John M.CEOJun 30 '26Sale34.3125,000857,6851,047,205Jul 01
Evans John M.CEOJun 29 '26Option Exercise0.7625,00019,0311,065,868Jul 01
Evans John M.CEOJun 29 '26Sale35.4925,000887,3521,047,205Jul 01
FMR LLC10% Owner, See Remark 1Jun 26 '26Sale35.26251,4888,867,467854,583Jun 29
FMR LLC10% Owner, See Remark 1Jun 25 '26Sale35.1233,3721,172,0251,106,071Jun 29
Ciaramella GiuseppePresidentJun 17 '26Option Exercise0.9635,50534,228253,911Jun 22
Simon AmyChief Medical OfficerApr 01 '26Sale24.586,700164,686102,735Apr 06
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.